What is the CPT code for Xofigo?
The recommended dose and schedule for Xofigo® is 55 kBq/kg (1.49 microcuries/kg) administered by slow intravenous injection over 1 minute every 4 weeks for 6 doses. Submit: HCPCS code A9606.
What is CPT A9606?
HCPCS code A9606 for Radium Ra-223 dichloride, therapeutic, per microcurie as maintained by CMS falls under Diagnostic and Therapeutic Radiopharmaceuticals .
Does Medicare pay for Xofigo?
Medicare benefits for Xofigo Original Medicare’s Part A benefits will apply if you receive Xofigo during a stay in a skilled nursing facility after a qualifying surgery.
What is Xofigo therapy?
Xofigo is a radioactive targeted therapy. This means that it has 2 main parts: a radioactive part and a tumor-targeted part. The tumor-targeted part helps the medication fight just the tumor cells, not your normal cells. This helps keep the medication from damaging healthy parts of your body.
How do I bill for Xofigo?
In a freestanding center or hospital outpatient setting, Xofigo is reported using the product-specific HCPCS A-code, A9606 (radium Ra 223 dichloride, therapeutic, per microcurie).
How is Xofigo administered?
Administer Xofigo by slow intravenous injection over 1 minute. Flush the intravenous access line or cannula with isotonic saline before and after injection of Xofigo. Xofigo (an alpha particle-emitting pharmaceutical) should be received, used and administered only by authorized persons in designated clinical settings.
What does Xofigo cost?
One concern about these new treatments is their high cost — Xofigo costs $69,000 for six injections, Bayer said. “They’re adding two to three months, for a huge cost.
What type of drug is Xofigo?
Xofigo is a type of drug called a radiopharmaceutical. It contains the active drug radium-223. This is a form of radium that gives off small amounts of radiation. Xofigo is absorbed into your bones, and the radiation kills the cancer cells there.
How is radium-223 administered?
You have radium 223 as an injection into a vein. Usually this is through a thin short tube (cannula) which is put into a vein in your arm or hand each time you have treatment. The injection takes around a minute. You normally have the injection every 4 weeks.
Who makes Xofigo?
Bayer Healthcare manufactures Xofigo, its targeted agent for fighting prostate cancer that has spread to the bone, at a plant in Norway.
Who can administer Xofigo?
Xofigo is an alpha particle-emitting therapy that is administered by a nuclear medicine specialist or a radiation oncologist in a designated clinical setting.
How much does radium-223 cost?
Cost for radium-223 was $69,000-$82,800 (€52,600-67,900) in a six-month course of treatment.
How much is Xofigo?
How long does Xofigo extend life?
XOFIGO SIGNIFICANTLY EXTENDS OVERALL SURVIVAL (OS) Median OS was 14.0 months (95% CI: 12.1-15.8) for Xofigo + best standard of care (BSOC) vs 11.2 months for BSOC (95% CI: 9.0-13.2).
When do you use Xofigo?
Xofigo is used when castration (to stop the production of male hormones) by surgery or with medicines does not work, and when the cancer has spread to the bones (bone metastases) and is causing symptoms such as pain, but has not spread to other internal organs.
What is radium Ra 223 dichloride used for?
On May15, 2013, the U. S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo ® Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
In a freestanding center or hospital outpatient setting, Xofigo is reported using the product-specific HCPCS A-code, A9606 (radium Ra 223 dichloride, therapeutic, per microcurie). 1
What is the volume of radium 223 dichloride in a vial?
Injectable Administration Radium-223 dichloride is available in 6 mL single use vials containing 1,100 kBq/mL (30 microcurie/mL) at the reference date. Use universal precautions to avoid contamination, including gloves and barrier gowns, when handling blood and body fluids.
What is the prognosis of Radium-223 dichloride (radium)?
Radium-223 dichloride is a radiopharmaceutical isotope that decays and is not metabolized. After correcting for decay, approximately 63% of the administered radioactivity was excreted from the body within 7 days of administration, with 13% (range, 0% to 34%) in fecal matter at 48 hours and 2% (range, 1% to 5%) in urine.